Boji Medical Technology Co., Ltd Boji Medical Technology Co., Ltd
EN
CN EN
OA系统
Services and Solutions

Nervous system

Covering peripheral neuropathy, Alzheimer's disease, and pediatric neurological disorders, with extensive experience in pediatric neurology specialties including ADHD and infantile spasms. Actively advancing cutting-edge clinical trials such as gene therapy for Duchenne muscular dystrophy (DMD) and stem cell therapy for Alzheimer's disease (AD).

Nervous system
Clinical Research Services Pre-Clinical Research TCM FC-RS Therapeutic Areas Global New Drug Development Services Ongoing Project Transfer
Tumor Tumor

Tumor
Anti-infective Anti-infective

Anti-infective
Pain Pain

Pain
Ophthalmology Ophthalmology

Ophthalmology
Urology/Andrology Urology/Andrology

Urology/Andrology
Cardiovascular System Cardiovascular System

Cardiovascular System
Endocrinology and Metabolism Endocrinology and Metabolism

Endocrinology and Metabolism
Nervous system Nervous system

Nervous system
Respiratory System Respiratory System

Respiratory System
Renal System Renal System

Renal System
Skin System Skin System

Skin System
Orthopedics Orthopedics

Orthopedics
Digestive System Digestive System

Digestive System

INTRODUCTION

Neurological disorders encompass a wide range of conditions affecting both the central and peripheral nervous systems, such as peripheral neuropathy and Alzheimer's disease.

 

Boji Pharmaceutical possesses extensive experience in managing neurology projects. In pediatric neurology, the company has completed and is currently collaborating on multiple Phase I/II/III clinical trials concerning ADHD, infantile spasms, pediatric seizures, and pediatric sedation. It is advancing clinical projects including gene therapy for Duchenne muscular dystrophy and stem cell therapy for Alzheimer's disease.

Clinical Research Project Experience

  • Infantile spasms
  • Infantile convulsions
  • Pediatric Sedation
  • Alzheimer's disease
  • Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents
  • Huntington's disease
  • Peripheral neuropathy, etc.

PROJECT EXPERIENCE

Assisted in the successful approval and market launch of Risperidone Microspheres for Injection (II)

Assisted in the successful approval and market launch of Risperidone Microspheres for Injection (II)

In January 2021, Shandong Luye Pharma Co., Ltd.'s Category 2 chemical new drug—Risperidone Microspheres for Injection (II) (brand name: Ruixintuo®)—received marketing approval from the National Medical Products Administration (NMPA). It is indicated for treating prominent positive and negative symptoms in acute and chronic schizophrenia, as well as other psychotic conditions. This drug represents China's first independently developed, globally registered innovative microsphere formulation with proprietary intellectual property rights, breaking foreign technological monopolies.

Leveraging extensive experience and a professional team, Boji Pharmaceutical provided scientific and rigorous management services for the clinical trials of this project, ensuring their smooth execution.

Previous :

Next :

Close